- Home
- TRIB vs GTBP Comparison
TRIB vs GTBP Comparison
Compare TRIB & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- GTBP
- Stock Information
- Founded
- TRIB 1992
- GTBP 1965
- Country
- TRIB Ireland
- GTBP United States
- Employees
- TRIB N/A
- GTBP N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- GTBP Health Care
- Exchange
- TRIB Nasdaq
- GTBP Nasdaq
- Market Cap
- TRIB 5.4M
- GTBP 5.5M
- IPO Year
- TRIB N/A
- GTBP N/A
- Fundamental
- Price
- TRIB $1.20
- GTBP $0.81
- Analyst Decision
- TRIB
- GTBP Strong Buy
- Analyst Count
- TRIB 0
- GTBP 1
- Target Price
- TRIB N/A
- GTBP $11.00
- AVG Volume (30 Days)
- TRIB 2.4M
- GTBP 449.7K
- Earning Date
- TRIB 11-14-2025
- GTBP 11-13-2025
- Dividend Yield
- TRIB N/A
- GTBP N/A
- EPS Growth
- TRIB N/A
- GTBP N/A
- EPS
- TRIB N/A
- GTBP N/A
- Revenue
- TRIB $61,555,000.00
- GTBP N/A
- Revenue This Year
- TRIB $13.51
- GTBP N/A
- Revenue Next Year
- TRIB $13.14
- GTBP N/A
- P/E Ratio
- TRIB N/A
- GTBP N/A
- Revenue Growth
- TRIB 8.31
- GTBP N/A
- 52 Week Low
- TRIB $0.48
- GTBP $0.63
- 52 Week High
- TRIB $3.44
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- TRIB 49.30
- GTBP 31.14
- Support Level
- TRIB $1.42
- GTBP $0.78
- Resistance Level
- TRIB $1.28
- GTBP $0.85
- Average True Range (ATR)
- TRIB 0.09
- GTBP 0.09
- MACD
- TRIB -0.03
- GTBP 0.03
- Stochastic Oscillator
- TRIB 26.67
- GTBP 49.14
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.